期刊
JOURNAL OF RHEUMATOLOGY
卷 39, 期 -, 页码 24-28出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.120237
关键词
PSORIASIS; METABOLIC SYNDROME; DYSLIPIDEMIA; HYPERGLYCEMIA; OBESITY
类别
资金
- U.S. National Institutes of Health
- National Heart, Lung, and Blood Institute [R01-HL089744]
- National Institutes of Arthritis and Musculoskeletal and Skin Disease [T32-AR07465]
- Abbott
- Amgen
- Genentech
- Novartis
- Pfizer
Psoriasis is a common Th-1 and Th-17-mediated chronic inflammatory disease that has been associated with metabolic syndrome, a constellation of cardiovascular risk factors including obesity, hypertension, dyslipidemia, and insulin resistance. Overlapping inflammatory pathways and genetic susceptibility may be potential biologic links underlying this association. Multiple epidemiologic studies have consistently demonstrated higher prevalence of metabolic syndrome in patients with psoriasis. Dose-response relationships between more severe psoriasis and higher prevalence of metabolic syndrome components were recently established. This association has important clinical implications for the comprehensive management of psoriasis: Patients with psoriasis should be routinely screened for metabolic syndrome and treated accordingly to manage cardiometabolic risk, while clinicians should monitor potential effects on treatment efficacy and safety in patients with comorbid psoriasis and metabolic syndrome. Further research will be necessary to establish the directionality of this association and to explore the effect of treatment on these comorbid diseases. (J Rheumatol 2012;39 Suppl 89:24-28; doi:10.3899/jrheum.120237)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据